Last updated on October 2018

An Open-Label Crenezumab Study in Patients With Alzheimer's Disease


Brief description of study

In the BN40031 OLE study, a dose of crenezumab of 60 mg/kg IV Q4W will be offered to all patients who complete Study BN29552 or BN29553 and who meet eligibility criteria in order to evaluate safety in patients on long-term crenezumab treatment and to investigate the effect of crenezumab on the underlying disease process and disease course as an exploratory efficacy objective.

Clinical Study Identifier: NCT03491150

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: BN40031 ...

Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre
Heidelberg West, Australia
2.13miles
  Connect »

Reference Study ID Number: BN40031 ...

Caulfield Hospital; Aged Psychiatry Research Unit
Caulfield, Australia
9.79miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.